IL-17, IL-23 and Other Cytokine Targets: Lessons from Clinical Trials for Spondyloarthritis

Moderator(s)

• 

  Ellen Gravallese, MD

  Brigham and Women's Hospital, Harvard Medical School

Speaker(s)

• 

  Joerg Ermann, MD

  Brigham and Women's Hospital
• CR

  Christopher Ritchlin, MD, MPH

  University of Rochester Medical Center

In recent years, a pathophysiological role for the IL-23-IL-17 pathway in the development of psoriasis, enthesitis and inflammatory arthritis has been defined. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). At this session, faculty will review the findings and discuss the relationship to murine models, as these data have begun to rationalize emerging hypotheses on the differential roles of these cytokines to pathogenesis.

Learning Objectives:

• Discuss the genetic basis for susceptibility for the development of spondyloarthritis
• Consider the relevance of rodent models to insights into autoimmune and inflammatory pathways of pathogenesis
• Review current data on the contributions of the IL-17-23 axis and other pro-inflammatory cytokine pathways, and the clinical benefits from antibody blockade for the amelioration of disease manifestations

Presentations:

• 11:00 AM – 11:20 AM ET

  IL-17, IL-23 and Other Cytokine Targets: Lessons from Clinical Trials for Spondyloarthritis
  Christopher Ritchlin, MD, MPH – University of Rochester Medical Center
• 11:20 AM – 11:40 AM ET

  IL-17, IL-23 and Other Cytokine Targets: Lessons from Clinical Trials for Spondyloarthritis
  Joerg Ermann, MD – Brigham and Women's Hospital
• 11:40 AM – 12:00 PM ET

  Q&A